Drug Profile
Lademirsen - Regulus Therapeutics
Alternative Names: Lademirsen sodium; RG 012; RG 456070; SAR 339375Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Regulus Therapeutics; Sanofi
- Class Antisense oligoribonucleotides; MicroRNAs; Urologics
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hereditary nephritis
Most Recent Events
- 07 Apr 2023 Sanofi terminates its R & D agreement with Regulus Therapeutics for Lademirsen
- 28 Jul 2022 Discontinued - Phase-II for Hereditary nephritis in USA, Spain, Germany, France, China, Canada, Australia, United Kingdom (SC) as of July 2022
- 28 Feb 2022 Regulus Therapeutics completes enrolment in the phase II HERA trial in Alport syndrome